Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin's lymphoma of B-cell type (B-NHL)

1997 ◽  
Vol 75 (5-6) ◽  
pp. 227-230 ◽  
Author(s):  
J. Braess ◽  
K. Reich ◽  
S. Willert ◽  
F. Strutz ◽  
C. Neumann ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Low Grade ◽  
Type B ◽  
Cell Type ◽  
Autoimmune Syndrome ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

P-021: Hyponatremia in non-Hodgkin's lymphoma diffuse large B cell type of the elderly

2015 ◽  
Vol 6 ◽  
pp. S37
Author(s):  
N. Kazuhiko ◽  
S. Ishihara ◽  
D. Nagase ◽  
Y. Mitsui ◽  
A. Sakai ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
The Elderly ◽  
Hodgkin's Lymphoma ◽  
Cell Type ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Large B Cell

Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up

2004 ◽  
Vol 22 (23) ◽  
pp. 4711-4716 ◽  
Author(s):  
Myron S. Czuczman ◽  
Robin Weaver ◽  
Baha Alkuzweny ◽  
Judy Berlfein ◽  
Antonio J. Grillo-López
Keyword(s):  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Complete Response ◽  
Hodgkin's Lymphoma ◽  
Low Grade ◽  
Molecular Remission ◽  
Prior Chemotherapy ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Purpose Long-term follow-up with updated time to disease progression (TTP) and duration of response (DR) data are presented from a multicenter, phase II trial of rituximab/cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) combination therapy in 40 patients with CD20+, B-cell, non-Hodgkin's lymphoma (NHL). Revised response rates based on International Workshop Response Criteria are also provided. Patients and Methods Enrollment began in April 1994 and consisted of patients with histologically confirmed, low-grade, B-cell lymphoma who had received no prior chemotherapy or who had no more than four prior standard therapies. Patients received six cycles of CHOP and six infusions of rituximab. Results Eight (21%) of the 38 treated patients were classified as International Working Formulation (IWF) A, 16 (42%) were IWF B, 13 (34%) were IWF C, and one (3%) was IWF D. Nine (24%) of 38 patients had received prior chemotherapy. Nine (24%) of 38 were considered poor risk according to the Follicular Lymphoma International Prognostic Index. Overall response rate was 100%; 87% of patients achieved a complete response or unconfirmed complete response. The median TTP and DR were 82.3 months and 83.5 months, respectively. Seven of eight patients who were bcl-2 positive at baseline converted to negative, and three of the seven patients have sustained the molecular remission. Conclusion Although a cure has not been found yet for follicular NHL, the R-CHOP combination provides a lengthy response duration in patients with relapsed or newly diagnosed indolent NHL.

Hemophagocytic syndrome associated with non-hodgkin's lymphoma of B-cell type

1994 ◽  
Vol 47 (4) ◽  
pp. 335-336 ◽  
Author(s):  
Tetsuya Nakamoto ◽  
Seishi Ogawa ◽  
Hiroyuki Mano ◽  
Hisamaru Hirai ◽  
Yoshio Yazaki
Keyword(s):  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Hemophagocytic Syndrome ◽  
Hodgkin's Lymphoma ◽  
Cell Type ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Two Resected Cases of Primary Pulmonary Non-Hodgkin's Lymphoma (B-cell, Diffuse, Small Cell Type).

Haigan ◽  
1993 ◽  
Vol 33 (7) ◽  
pp. 1083-1089
Author(s):  
Toshinori Hashizume ◽  
Keiichi Kikuchi ◽  
Toyohiko Tsurumi ◽  
Yotaro Izumi ◽  
Chikao Torikata
Keyword(s):  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Small Cell ◽  
Hodgkin's Lymphoma ◽  
Cell Type ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Mediastinal Non-Hodgkin's Lymphoma Metastatic to Right Atrium Mimicking Right Atrial Myxoma

2021 ◽  
Vol 57 (4) ◽  
pp. 345
Author(s):  
Gemilang Khusnurrokhman ◽  
Laksmi Wulandari
Keyword(s):  
B Cell ◽  
Right Atrium ◽  
Hodgkin’S Lymphoma ◽  
Atrial Myxoma ◽  
Hodgkin's Lymphoma ◽  
Right Atrial ◽  
Cell Type ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
The Right

Highlight:A 32-year-old male patient suffered mediastinal non-hodgkin's lymphoma metastatic to the right atrium which mimicked right atrial myxoma.The patient died of suspected mediastinal NHL thromboembolism that spread in the right atrium. Abstract:In this case report, the anatomical pathology results in the form of B cell type LNH, but at the age of 32 years and the risk factor in this patient was a former active smoker. In the anatomical pathology results, the results of the B-High Grade Cell Type LNH were also obtained. B-cell type non-hodgkin’s lymphoma can be mutated in the MYC gene (v-myc avian myceloctomatosis viral oncogene homolog) and the BCL-2 and BCL-6 (B-cell lymphoma) genes. If this morphology is found, then the patient's prognosis is poor. Most of these patients were males and the incidence was in the mediastinal area. Mediastinal NHL could develop and enlarge to involve the heart and pericardium. The spread could occur directly and lymphogens. These metastatic tumors were often misdiagnosed with atrial myxoma. In this case report, exploration of the right atrium and open mediastinal biopsy was performed. An open biopsy of the mediastinum revealed a mediastinal mass that enlarged to enter the right atrium. Atrial myxoma was not found. Primary lymphoma growth could also occur in the heart. This condition was called primary cardiac lymphoid (PCL). This case was very rare and was often considered an atrial myxoma. The patient died 10 days after discharge from the hospital. While the patient was eating, the patient had a seizure and the patient was immediately taken to the emergency department of Dr. Soetomo General Academic Hospital, Surabaya, and entered the ER (Resuscitation) ER room, but the patient died after being assisted for approximately two hours. Most likely the cause of the patient's death was a thromboembolic tumor in the right atrium that was released, so that it entered the bloodstream of the brain, causing the patient to have seizures. It was suspected that the cause of the patient's death was the presence of a tumor thrombus that separated into an embolism from the right atrium due to the large size of the tumor. Patients suffering from high rate NHL had a greater percentage of suffering from tumor thromboembolism as many as 10.6% compared to the Low type and Hodgkins lymphoma (LH) (5.8% and 7.25%).

Phase II Study of Denileukin Diftitox for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

2004 ◽  
Vol 22 (20) ◽  
pp. 4095-4102 ◽  
Author(s):  
Nam H. Dang ◽  
Fredrick B. Hagemeister ◽  
Barbara Pro ◽  
Peter McLaughlin ◽  
Jorge E. Romaguera ◽  
...  
Keyword(s):  
B Cell ◽  
Phase Ii ◽  
Stable Disease ◽  
Hodgkin’S Lymphoma ◽  
Phase Ii Study ◽  
Hodgkin's Lymphoma ◽  
Low Grade ◽  
Denileukin Diftitox ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Purpose Denileukin diftitox is a fusion protein combining diphtheria toxin and interleukin-2 (IL-2) that targets tumor cells expressing the IL-2 receptor. Its efficacy has been shown in CD25+ cutaneous T-cell lymphoma, but not in B-cell non-Hodgkin's lymphoma (NHL). A phase II study was performed to evaluate the efficacy and tolerability of denileukin diftitox for relapsed or refractory B-cell NHL. Patients and Methods Patients with relapsed or refractory B-cell NHL were eligible. Tumor CD25 expression was determined by immunohistochemistry or flow cytometry. Denileukin diftitox was administered intravenously at a dose of 18 μg/kg once daily for 5 days every 3 weeks, up to eight cycles. Results Of the 45 patients assessable for response, 32 (71%) were refractory to the last chemotherapy treatment, and all were previously treated with rituximab. Three complete responses (6.7%) and eight partial responses (17.8%) were observed, for an overall response rate of 24.5%. Nine patients (20%) had stable disease. Objective response rates were similar in CD25+ (22%) and CD25− histologies (29%), as were stable disease rates (22% and 18%, respectively). For responding patients, the median time to treatment failure was 7 months, with a median follow-up in survivors of 18 months (range, 9 to 28 months), and the projected progression-free survival at 20 months was 24% (95% CI, 0% to 60%). Most toxicities were low-grade and transient. Conclusion Denileukin diftitox seems to be effective in relapsed or refractory, CD25+ and CD25− B-cell NHL and is well-tolerated at the dosage evaluated. Evaluation of denileukin diftitox in combination with other agents may be warranted.

Spontaneous Regression in B Cell, Diffuse Large Cell Type Non-Hodgkin’s Lymphoma

1993 ◽  
Vol 90 (1) ◽  
pp. 46-47 ◽  
Author(s):  
J. Tamura ◽  
T. Jinbo ◽  
H. Take ◽  
T. Matsushima ◽  
M. Sawamura ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Spontaneous Regression ◽  
Large Cell ◽  
Hodgkin's Lymphoma ◽  
Cell Type ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma
Sign in / Sign up

Export Citation Format

Share Document